Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hospital of ChinaHKSE:03869 73 EBITDA Margin % is 3.69% as of Dec. 2025, which is 80% below its 10-year median of 18.66. GuruFocus rates HKSE:03869 with a GF Score™ of 73/100 and a GF Value™ of HK$5.53 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 671 Healthcare Providers & Services companies, Hospital of China ranks better than 73.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hospital of China's EBITDA for the
six
months ended in Dec. 2025 was HK$30 Mil. Hospital of China's Revenue for the
six
months ended in Dec. 2025 was HK$804 Mil. Therefore, Hospital of China's EBITDA margin for the quarter that ended in Dec. 2025 was 3.69%.
Hospital of China (HKSE:03869) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hospital of China EBITDA Margin % Related Terms
Hospital of China EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hospital of China's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03869 vs HCA, THC, EHC: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Hospital of China's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospital of China EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hospital of China's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hospital of China's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hospital of China (HKSE:03869) has a EBITDA Margin % of 3.69% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hospital of China and its competitors. This is 80% below median its historical median of 18.66. According to the industry distribution chart, Hospital of China ranks #178 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 26.5%.
Is Hospital of China's EBITDA Margin % too high?
Hospital of China's current EBITDA Margin % of 3.69% is 80% below median its 10-year median of 18.66. The Healthcare Providers & Services industry median EBITDA Margin % is 10.09. Hospital of China's value of 3.69% is 63.4% below this industry median. Based on the distribution chart, Hospital of China ranks #178 out of 671 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Hospital of China has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hospital of China's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital of China ranks #178 out of 671 companies for EBITDA Margin %. This puts Hospital of China in the upper half of its industry. The industry median EBITDA Margin % is 10.09. Hospital of China's value of 3.69% is 63.4% below this benchmark. While the company's 10-year median is 18.66 vs. the industry median of 10.09, Hospital of China has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.09, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital of China's current EBITDA Margin % of 3.69% is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hospital of China and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital of China's current EBITDA Margin % is 3.69%, which is 80% below median its own 10-year median of 18.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital of China stock overvalued right now?
Based on GuruFocus' analysis, Hospital of China (HKSE:03869) is currently considered Possible Value Trap. The stock's GF Value™ is HK$5.53, compared to a current price of HK$3.40 — trading 38.5% below its estimated fair value. The current EBITDA Margin % is 3.69%, which is 80% below median its 10-year median of 18.66 and 63.4% below the Healthcare Providers & Services industry median of 10.09. Hospital of China's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hospital of China (HKSE:03869), the current EBITDA Margin % is 3.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital of China (HKSE:03869) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital of China stock appears to be undervalued.
The current stock price of HK$3.40 is trading 38.5% below its estimated GF Value™ of HK$5.53.
GuruFocus considers Hospital of China to be Possible Value Trap.
Key valuation signals for HKSE:03869:
EBITDA Margin %: 3.69% (80% below median its 10-year median of 18.66)
GF Value™: HK$5.53 vs. price of HK$3.40 (38.5% below fair value)
Industry Position: 63.4% below the Healthcare Providers & Services median (#178 of 671)
No single metric tells the full story. See the HKSE:03869 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Corporation of China Ltd is an investment holding company that operates and manages hospitals in the People's Republic of China. In addition to offering hospital management services, it also provides supply chain services, other ancillary services, and sells pharmaceutical products. The company has three operating segments, namely, Hospital management services, General hospital services, and the sale of pharmaceutical products. The General Hospital services segment is the primary revenue generator for the company. All the company's revenue is generates from PRC.
73GF Score
Get the complete analysis for HKSE:03869
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03869 has been successfully added to your 
